DLL4 and cancer: For instance, at the American Association of Cancer Research (AACR) 106th Annual Meeting 2015, dual targeting of delta-like ligand 4 (DLL4) and programmed death 1 (PD1) was demonstrated to be a promising cancer therapy [191].